Hansoh Pharmaceutical Group Company Limited (翰森製藥集團有限公司), known as Hansoh Pharma, is a leading innovation-driven pharmaceutical company headquartered in Shanghai, China. Founded in 1995, it is listed on the Hong Kong Stock Exchange (3692.HK) and operates primarily through its principal subsidiary, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., based in Lianyungang, Jiangsu.
The company focuses on research, development, manufacturing, and sales of pharmaceuticals across key therapeutic areas including oncology, anti-infectives, central nervous system disorders, metabolic diseases, and autoimmune conditions. It has launched seven innovative drugs in China, such as aumolertinib mesylate (Ameile) for EGFR-mutant non-small cell lung cancer, flumatinib mesylate (Hansoh Xinfu) for chronic myelogenous leukemia, and pegmolesatide injection (Saint Luolai) for renal anemia. Hansoh maintains a robust pipeline with over 40 innovative candidates in more than 70 clinical trials.
Recognized among the top 100 global pharmaceutical companies and top 3 in China's pharmaceutical R&D pipelines, it holds national high-tech enterprise status and has partnered globally, including licensing deals with GSK, Roche, and Merck for assets like risvutatug rezetecan (HS-20093), an antibody-drug conjugate targeting B7-H3.
To provide comprehensive coverage, we aggregate data and news under the name Hansoh Pharma, encompassing the following company names, divisions, and related entities:
江苏豪森药业集团有限公司 and Jiangsu Hansoh Pharmaceutical Group Co., Ltd..
This list encompasses current and former names, alternate names, and key divisions associated with Hansoh Pharma, ensuring you can easily find all relevant information under a single, unified profile.
